Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 182

1.

Publisher Correction: Progenitors from the central nervous system drive neurogenesis in cancer.

Mauffrey P, Tchitchek N, Barroca V, Bemelmans AP, Firlej V, Allory Y, Roméo PH, Magnon C.

Nature. 2020 Jan 8. doi: 10.1038/s41586-019-1837-4. [Epub ahead of print]

PMID:
31911658
2.

Combined MEK and PI3K/p110b inhibition as a novel targeted therapy for malignant mesothelioma displaying sarcomatoid features.

Marqués M, Tranchant R, Risa-Ebrí B, Suárez-Solís ML, Fernández LC, Carrillo-de-Santa-Pau E, Del Pozo N, Martínez de Villarreal J, Meiller C, Allory Y, Blum Y, Pirker C, Hegedus B, Barry ST, Carnero A, Berger W, Jean D, Real FX.

Cancer Res. 2020 Jan 7. pii: canres.1633.2019. doi: 10.1158/0008-5472.CAN-19-1633. [Epub ahead of print]

PMID:
31911549
3.

Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group.

Sroussi M, Elaidi R, Fléchon A, Lorcet M, Borchiellini D, Tardy MP, Gravis G, Guérin M, Laguerre B, Estrade F, Delva R, Barthélémy P, Loriot Y, Lavaud P, Lebret T, Neuzillet Y, Penel N, Houede N, Pouessel D, Rousseau B, Mussat E, Gross-Goupil M, Culine S, Gauthier H, Gobert A, Roupret M, Huillard O, Tartas S, Radulescu C, Allory Y, Oudard S.

Clin Genitourin Cancer. 2019 Dec 5. pii: S1558-7673(19)30365-9. doi: 10.1016/j.clgc.2019.11.014. [Epub ahead of print]

PMID:
31882335
4.

Diesel exhaust and bladder cancer risk by pathologic stage and grade subtypes.

Koutros S, Kogevinas M, Friesen MC, Stewart PA, Baris D, Karagas MR, Schwenn M, Johnson A, Monawar Hosain GM, Serra C, Tardon A, Carrato A, Garcia-Closas R, Moore LE, Nickerson ML, Hewitt SM, Lenz P, Schned AR, Lloreta J, Allory Y, Zhang H, Chatterjee N, Garcia-Closas M, Rothman N, Malats N, Silverman DT.

Environ Int. 2020 Feb;135:105346. doi: 10.1016/j.envint.2019.105346. Epub 2019 Dec 18.

5.

Reference-free transcriptome exploration reveals novel RNAs for prostate cancer diagnosis.

Pinskaya M, Saci Z, Gallopin M, Gabriel M, Nguyen HT, Firlej V, Descrimes M, Rapinat A, Gentien D, Taille A, Londoño-Vallejo A, Allory Y, Gautheret D, Morillon A.

Life Sci Alliance. 2019 Nov 15;2(6). pii: e201900449. doi: 10.26508/lsa.201900449. Print 2019 Dec.

6.

A Consensus Molecular Classification of Muscle-invasive Bladder Cancer.

Kamoun A, de Reyniès A, Allory Y, Sjödahl G, Robertson AG, Seiler R, Hoadley KA, Groeneveld CS, Al-Ahmadie H, Choi W, Castro MAA, Fontugne J, Eriksson P, Mo Q, Kardos J, Zlotta A, Hartmann A, Dinney CP, Bellmunt J, Powles T, Malats N, Chan KS, Kim WY, McConkey DJ, Black PC, Dyrskjøt L, Höglund M, Lerner SP, Real FX, Radvanyi F; Bladder Cancer Molecular Taxonomy Group.

Eur Urol. 2019 Sep 26. pii: S0302-2838(19)30695-5. doi: 10.1016/j.eururo.2019.09.006. [Epub ahead of print]

7.

PLEKHS1: A new molecular marker predicting risk of progression of non-muscle-invasive bladder cancer.

Pignot G, Le Goux C, Vacher S, Schnitzler A, Radvanyi F, Allory Y, Lallemand F, Delongchamps NB, Zerbib M, Terris B, Damotte D, Bieche I.

Oncol Lett. 2019 Oct;18(4):3471-3480. doi: 10.3892/ol.2019.10706. Epub 2019 Aug 2.

8.

High Positive Correlations between ANRIL and p16-CDKN2A/p15-CDKN2B/p14-ARF Gene Cluster Overexpression in Multi-Tumor Types Suggest Deregulated Activation of an ANRIL-ARF Bidirectional Promoter.

Drak Alsibai K, Vacher S, Meseure D, Nicolas A, Lae M, Schnitzler A, Chemlali W, Cros J, Longchampt E, Cacheux W, Pignot G, Callens C, Pasmant E, Allory Y, Bieche I.

Noncoding RNA. 2019 Aug 21;5(3). pii: E44. doi: 10.3390/ncrna5030044.

9.

Distinct genetic alterations and luminal molecular subtype in nested variant of urothelial carcinoma.

Weyerer V, Weisser R, Moskalev EA, Haller F, Stoehr R, Eckstein M, Zinnall U, Gaisa NT, Compérat E, Perren A, Keck B, Allory Y, Kristiansen G, Wullich B, Agaimy A, Hartmann A, Bertz S.

Histopathology. 2019 Dec;75(6):865-875. doi: 10.1111/his.13958. Epub 2019 Oct 23.

10.

Erratum: CRIPTO overexpression promotes mesenchymal differentiation in prostate carcinoma cells through parallel regulation of AKT and FGFR activities.

Terry S, El-Sayed IY, Destouches D, Maillé P, Nicolaiew N, Ploussard G, Semprez F, Pimpie C, Beltran H, Londono-Vallejo A, Allory Y, de la Taille A, Salomon DS, Vacherot F.

Oncotarget. 2019 Jun 25;10(41):4247-4248. doi: 10.18632/oncotarget.27038. eCollection 2019 Jun 25.

11.

Progenitors from the central nervous system drive neurogenesis in cancer.

Mauffrey P, Tchitchek N, Barroca V, Bemelmans AP, Firlej V, Allory Y, Roméo PH, Magnon C.

Nature. 2019 May;569(7758):672-678. doi: 10.1038/s41586-019-1219-y. Epub 2019 May 15. Erratum in: Nature. 2020 Jan 8;:.

PMID:
31092925
12.

Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer.

Borcoman E, De La Rochere P, Richer W, Vacher S, Chemlali W, Krucker C, Sirab N, Radvanyi F, Allory Y, Pignot G, Barry de Longchamps N, Damotte D, Meseure D, Sedlik C, Bieche I, Piaggio E.

Oncoimmunology. 2019 Mar 16;8(5):e1581556. doi: 10.1080/2162402X.2019.1581556. eCollection 2019.

13.

[Testicular germ cell tumors: Histopathological and molecular features].

Tourne M, Radulescu C, Allory Y.

Bull Cancer. 2019 Apr;106(4):328-341. doi: 10.1016/j.bulcan.2019.02.004. Epub 2019 Mar 21. Review. French.

PMID:
30905378
14.

TYRO3 as a molecular target for growth inhibition and apoptosis induction in bladder cancer.

Dufour F, Silina L, Neyret-Kahn H, Moreno-Vega A, Krucker C, Karboul N, Dorland-Galliot M, Maillé P, Chapeaublanc E, Allory Y, Stransky N, Haegel H, Menguy T, Duong V, Radvanyi F, Bernard-Pierrot I.

Br J Cancer. 2019 Mar;120(5):555-564. doi: 10.1038/s41416-019-0397-6. Epub 2019 Feb 15.

PMID:
30765874
15.

Stromal lymphocyte infiltration is associated with tumour invasion depth but is not prognostic in high-grade T1 bladder cancer.

Rouanne M, Betari R, Radulescu C, Goubar A, Signolle N, Neuzillet Y, Allory Y, Marabelle A, Adam J, Lebret T.

Eur J Cancer. 2019 Feb;108:111-119. doi: 10.1016/j.ejca.2018.12.010. Epub 2019 Jan 14.

PMID:
30654296
16.

Recurrent activating mutations of PPARγ associated with luminal bladder tumors.

Rochel N, Krucker C, Coutos-Thévenot L, Osz J, Zhang R, Guyon E, Zita W, Vanthong S, Hernandez OA, Bourguet M, Badawy KA, Dufour F, Peluso-Iltis C, Heckler-Beji S, Dejaegere A, Kamoun A, de Reyniès A, Neuzillet Y, Rebouissou S, Béraud C, Lang H, Massfelder T, Allory Y, Cianférani S, Stote RH, Radvanyi F, Bernard-Pierrot I.

Nat Commun. 2019 Jan 16;10(1):253. doi: 10.1038/s41467-018-08157-y.

17.

High Prevalence of a Hotspot of Noncoding Somatic Mutations in Intron 6 of GPR126 in Bladder Cancer.

Garinet S, Pignot G, Vacher S, Le Goux C, Schnitzler A, Chemlali W, Sirab N, Barry Delongchamps N, Zerbib M, Sibony M, Allory Y, Damotte D, Bieche I.

Mol Cancer Res. 2019 Feb;17(2):469-475. doi: 10.1158/1541-7786.MCR-18-0363. Epub 2018 Nov 6.

PMID:
30401719
18.

Refining the use of neoadjuvant chemotherapy in locally advanced bladder cancer: from conviction to optimization.

Culine S, Allory Y, Pfister C.

Transl Androl Urol. 2018 Aug;7(4):757-759. doi: 10.21037/tau.2018.06.11. No abstract available.

19.

Contemporary assessment of the correlation between Bosniak classification and histological characteristics of surgically removed atypical renal cysts (UroCCR-12 study).

Nouhaud FX, Bernhard JC, Bigot P, Khene ZE, Audenet F, Lang H, Bergerat S, Fraisse G, Grenier N, Cornelis F, Nedelcu C, Béjar S, Fromont-Hankard G, Allory Y, Lindner V, Verkarre V, Daniel L, Yacoub M, Correas JM, Méjean A, Rioux-Leclercq N, Bensalah K.

World J Urol. 2018 Oct;36(10):1643-1649. doi: 10.1007/s00345-018-2307-6. Epub 2018 May 5.

PMID:
29730837
20.

Reappraisal of HER2 status in the spectrum of advanced urothelial carcinoma: a need of guidelines for treatment eligibility.

Moktefi A, Pouessel D, Liu J, Sirab N, Maille P, Soyeux P, Bergman CC, Auriault ML, Vordos D, Taille A, Culine S, Allory Y.

Mod Pathol. 2018 Aug;31(8):1270-1281. doi: 10.1038/s41379-018-0023-9. Epub 2018 Feb 21.

21.

Genito-urinary genomics and emerging biomarkers for immunomodulatory cancer treatment.

Gevaert T, Montironi R, Lopez-Beltran A, Van Leenders G, Allory Y, De Ridder D, Claessens F, Kockx M, Akand M, Joniau S, Netto G, Libbrecht L.

Semin Cancer Biol. 2018 Oct;52(Pt 2):216-227. doi: 10.1016/j.semcancer.2017.10.004. Epub 2017 Oct 12. Review.

PMID:
29032188
22.

DNA degrades during storage in formalin-fixed and paraffin-embedded tissue blocks.

Guyard A, Boyez A, Pujals A, Robe C, Tran Van Nhieu J, Allory Y, Moroch J, Georges O, Fournet JC, Zafrani ES, Leroy K.

Virchows Arch. 2017 Oct;471(4):491-500. doi: 10.1007/s00428-017-2213-0. Epub 2017 Aug 15.

PMID:
28812131
23.

Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB.

Adv Anat Pathol. 2017 Nov;24(6):311-335. doi: 10.1097/PAP.0000000000000161. Review.

24.

Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research.

Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB.

Adv Anat Pathol. 2017 Sep;24(5):235-251. doi: 10.1097/PAP.0000000000000162. Review.

25.

Prognostic Biomarkers Used for Localised Prostate Cancer Management: A Systematic Review.

Lamy PJ, Allory Y, Gauchez AS, Asselain B, Beuzeboc P, de Cremoux P, Fontugne J, Georges A, Hennequin C, Lehmann-Che J, Massard C, Millet I, Murez T, Schlageter MH, Rouvière O, Kassab-Chahmi D, Rozet F, Descotes JL, Rébillard X.

Eur Urol Focus. 2018 Dec;4(6):790-803. doi: 10.1016/j.euf.2017.02.017. Epub 2017 Mar 7.

PMID:
28753865
26.

Predictive factors for final pathologic ureteral sections on 700 radical cystectomy specimens: Implications for intraoperative frozen section decision-making.

Masson-Lecomte A, Francois T, Vordos D, Cordonnier C, Allory Y, Desgrandchamps F, de la Taille A, Saint F.

Urol Oncol. 2017 Nov;35(11):659.e1-659.e6. doi: 10.1016/j.urolonc.2017.06.053. Epub 2017 Jul 14.

PMID:
28716562
27.

Ductal adenocarcinoma of the prostate: Clinical and biological profiles.

Vinceneux A, Bruyère F, Haillot O, Charles T, de la Taille A, Salomon L, Allory Y, Ouzaid I, Choudat L, Rouprêt M, Comperat E, Houede N, Beauval JB, Vourc'h P, Fromont G.

Prostate. 2017 Sep;77(12):1242-1250. doi: 10.1002/pros.23383. Epub 2017 Jul 12.

PMID:
28699202
28.

Renal Medullary Carcinoma: Establishing Standards in Practice.

Beckermann KE, Sharma D, Chaturvedi S, Msaouel P, Abboud MR, Allory Y, Bourdeaut F, Calderaro J, de Cubas AA, Derebail VK, Hong AL, Naik RP, Malouf GG, Mullen EA, Reuter VE, Roberts CWM, Walker CL, Wood CG, DeBaun MR, Van Poppel H, Tannir NM, Rathmell WK.

J Oncol Pract. 2017 Jul;13(7):414-421. doi: 10.1200/JOP.2017.020909. Review.

29.

Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriers.

Muller M, Ferlicot S, Guillaud-Bataille M, Le Teuff G, Genestie C, Deveaux S, Slama A, Poulalhon N, Escudier B, Albiges L, Soufir N, Avril MF, Gardie B, Saldana C, Allory Y, Gimenez-Roqueplo AP, Bressac-de Paillerets B, Richard S, Benusiglio PR.

Clin Genet. 2017 Dec;92(6):606-615. doi: 10.1111/cge.13014. Epub 2017 May 2. Erratum in: Clin Genet. 2018 May;93(5):1118.

PMID:
28300276
30.

Large-Scale SRM Screen of Urothelial Bladder Cancer Candidate Biomarkers in Urine.

Duriez E, Masselon CD, Mesmin C, Court M, Demeure K, Allory Y, Malats N, Matondo M, Radvanyi F, Garin J, Domon B.

J Proteome Res. 2017 Apr 7;16(4):1617-1631. doi: 10.1021/acs.jproteome.6b00979. Epub 2017 Mar 23.

PMID:
28287737
31.

[Immunotherapy in uropathology].

Verkarre V, Roussel H, Granier C, Tartour E, Allory Y.

Ann Pathol. 2017 Feb;37(1):90-100. doi: 10.1016/j.annpat.2016.12.015. Epub 2017 Jan 19. Review. French.

PMID:
28111042
32.

[Bladder tumor histoseminar - Introduction. Bladder tumours diagnosis facing new treatments and new molecular classifications].

Allory Y.

Ann Pathol. 2016 Dec;36(6):371-372. doi: 10.1016/j.annpat.2016.09.012. Epub 2016 Nov 9. French. No abstract available.

PMID:
27838083
33.

[Bladder tumor histo-seminar - pre-test answers].

Allory Y.

Ann Pathol. 2016 Dec;36(6):410-411. doi: 10.1016/j.annpat.2016.09.009. Epub 2016 Nov 9. French. No abstract available.

PMID:
27838082
34.

[Bladder tumor histo-seminar - case 5: Urothelial carcinoma with squamous differentiation (basal type)].

Allory Y.

Ann Pathol. 2016 Dec;36(6):390-393. doi: 10.1016/j.annpat.2016.09.014. Epub 2016 Nov 9. Review. French. No abstract available.

PMID:
27838080
35.

[Bladder tumor histo-seminar - case 6: Invasive urothelial carcinoma, with inverted growth (UroA/FGFR3 molecular type)].

Allory Y.

Ann Pathol. 2016 Dec;36(6):394-397. doi: 10.1016/j.annpat.2016.09.010. Epub 2016 Nov 9. Review. French. No abstract available.

PMID:
27838079
36.

[Bladder tumor histo-seminar - pre-test].

Allory Y.

Ann Pathol. 2016 Dec;36(6):373-374. doi: 10.1016/j.annpat.2016.09.013. Epub 2016 Nov 9. French. No abstract available.

PMID:
27838076
37.

A prospective multicenter study on bladder cancer: the COBLAnCE cohort.

Benhamou S, Bonastre J, Groussard K, Radvanyi F, Allory Y, Lebret T.

BMC Cancer. 2016 Nov 3;16(1):837.

38.

Adjuvant Chemotherapy After Radical Cystectomy for Urothelial Bladder Cancer: Outcome and Prognostic Factors for Survival in a French Multicenter, Contemporary Cohort.

Pouessel D, Bastuji-Garin S, Houédé N, Vordos D, Loriot Y, Chevreau C, Sevin E, Beuzeboc P, Taille A, Le Thuaut A, Allory Y, Culine S.

Clin Genitourin Cancer. 2017 Feb;15(1):e45-e52. doi: 10.1016/j.clgc.2016.07.012. Epub 2016 Jul 21.

PMID:
27554584
39.

Validation of VEGFR1 rs9582036 as predictive biomarker in metastatic clear-cell renal cell carcinoma patients treated with sunitinib.

Beuselinck B, Jean-Baptiste J, Schöffski P, Couchy G, Meiller C, Rolland F, Allory Y, Joniau S, Verkarre V, Elaidi R, Lerut E, Roskams T, Patard JJ, Oudard S, Méjean A, Lambrechts D, Zucman-Rossi J.

BJU Int. 2016 Dec;118(6):890-901. doi: 10.1111/bju.13585. Epub 2016 Aug 12.

40.

Identification of targeted therapy for an aggressive subgroup of muscle-invasive bladder cancers.

Lebret T, Neuzillet Y, Houede N, Rebouissou S, Bernard-Pierrot I, De Reynies A, Benhamou S, Allory Y, Radvanyi F.

Mol Cell Oncol. 2015 Jul 9;2(4):e999507. doi: 10.1080/23723556.2014.999507. eCollection 2015 Oct-Dec.

41.

Inflammatory-Related Genetic Variants in Non-Muscle-Invasive Bladder Cancer Prognosis: A Multimarker Bayesian Assessment.

Masson-Lecomte A, López de Maturana E, Goddard ME, Picornell A, Rava M, González-Neira A, Márquez M, Carrato A, Tardon A, Lloreta J, Garcia-Closas M, Silverman D, Rothman N, Kogevinas M, Allory Y, Chanock SJ, Real FX, Malats N; SBC/EPICURO Study Investigators.

Cancer Epidemiol Biomarkers Prev. 2016 Jul;25(7):1144-50. doi: 10.1158/1055-9965.EPI-15-0894. Epub 2016 May 6.

42.

Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment.

Pouessel D, Neuzillet Y, Mertens LS, van der Heijden MS, de Jong J, Sanders J, Peters D, Leroy K, Manceau A, Maille P, Soyeux P, Moktefi A, Semprez F, Vordos D, de la Taille A, Hurst CD, Tomlinson DC, Harnden P, Bostrom PJ, Mirtti T, Horenblas S, Loriot Y, Houédé N, Chevreau C, Beuzeboc P, Shariat SF, Sagalowsky AI, Ashfaq R, Burger M, Jewett MA, Zlotta AR, Broeks A, Bapat B, Knowles MA, Lotan Y, van der Kwast TH, Culine S, Allory Y, van Rhijn BW.

Ann Oncol. 2016 Jul;27(7):1311-6. doi: 10.1093/annonc/mdw170. Epub 2016 Apr 18.

43.

Implication of NPM1 phosphorylation and preclinical evaluation of the nucleoprotein antagonist N6L in prostate cancer.

Destouches D, Sader M, Terry S, Marchand C, Maillé P, Soyeux P, Carpentier G, Semprez F, Céraline J, Allory Y, Courty J, De La Taille A, Vacherot F.

Oncotarget. 2016 Oct 25;7(43):69397-69411. doi: 10.18632/oncotarget.8043.

44.

Étude prospective multicentrique comparant les voies ouverte et mini-invasive de la prostatectomie totale (Propenlap : résultats fonctionnels).

Salomon L, Bastuji-Garin S, Soulie M, Devonec M, Boutin E, Mandron E, Benoit G, Rischmann P, Mottet N, Gasman D, Irani J, De la Taille A, Zerbib M, Vaesen C, Dore B, Lebret T, Colombel M, Lechevallier E, Gregoire L, Allory Y, Abbou C.

Prog Urol. 2015 Nov;25(13):793. doi: 10.1016/j.purol.2015.08.154. French. No abstract available.

PMID:
26544349
45.

Mesure de l'association entre variants inflammatoires et pronostic des tumeurs de vessie non invasives du muscle : comparaison de méthodes statistiques classiques et innovantes.

Mason-Lecomte A, Lopez de Maturana E, Rava M, Marques M, Allory Y, Real F, Malats N.

Prog Urol. 2015 Nov;25(13):761-2. doi: 10.1016/j.purol.2015.08.094. French. No abstract available.

PMID:
26544288
46.

Association entre les variants de PDL1 et le pronostic des tumeurs de vessie non invasive du muscle : résultats issus d'une cohorte de cancers de vessie prospective multicentrique.

Mason-Lecomte A, Lopez de Maturana E, Pineda S, Rava M, Vordos D, Allory Y, Real F, Malats N.

Prog Urol. 2015 Nov;25(13):758-9. doi: 10.1016/j.purol.2015.08.088. French. No abstract available.

PMID:
26544283
47.

Résultats économiques de Propenlap, étude prospective multicentrique comparant les voies ouvertes et mini-invasives de la prostatectomie totale.

Durand-Zaleski I, Rabetrano H, Devonec M, Mandron E, Soulie M, De la Taille A, Benoit G, Mottet N, Gasman D, Dore B, Zerbib M, Vaessen C, Irani J, Lebret T, Colombel M, Lechevallier E, Bastuji-Garin S, Allory Y, Abbou C, Rischmann P, Salomon L.

Prog Urol. 2015 Nov;25(13):742. doi: 10.1016/j.purol.2015.08.054. French. No abstract available.

PMID:
26544250
48.

Implication de la molécule X dans la récidive du cancer de prostate (CaP) localisé.

Champy C, Semprez F, El Sayed I, Maille P, Soyeux P, Allory Y, Vacherot F, De La Taille A, Firlej V.

Prog Urol. 2015 Nov;25(13):727. doi: 10.1016/j.purol.2015.08.024. French. No abstract available.

PMID:
26544219
49.

Comparaison des valeurs pronostiques des grades OMS 1973 et OMS 2004/ISUP dans une cohorte prospective de 968 tumeurs de vessie non invasives du muscle.

Masson-Lecomte A, Seijas R, Marquez M, Lloreta J, Kogevinas M, Algaba F, Real F, Malats N, Allory Y.

Prog Urol. 2014 Nov;24(13):848-9. doi: 10.1016/j.purol.2014.08.145. Epub 2014 Oct 30. French. No abstract available.

PMID:
26461671
50.

Méthode standardisée d'évaluation de l'infiltrat inflammatoire des carcinomes urothéliaux de vessie : reconnaissance tissulaire et comptage automatique.

Masson-Lecomte A, Maille P, Soyeux P, Real F, Malats N, Allory Y.

Prog Urol. 2014 Nov;24(13):847-8. doi: 10.1016/j.purol.2014.08.143. Epub 2014 Oct 30. French. No abstract available.

PMID:
26461668

Supplemental Content

Loading ...
Support Center